On Friday, Karyopharm Therapeutics Inc (NASDAQ: KPTI) opened lower -7.42% from the last session, before settling in for the closing price of $7.68. Price fluctuations for KPTI have ranged from $3.51 to $16.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.91% over the last five years. Company’s average yearly earnings per share was noted 17.50% at the time writing. With a float of $7.96 million, this company’s outstanding shares have now reached $8.65 million.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Karyopharm Therapeutics Inc is 8.21%, while institutional ownership is 58.63%. The most recent insider transaction that took place on Jul 29 ’25, was worth 835. In this transaction EVP, Chief Development Officer of this company sold 191 shares at a rate of $4.37, taking the stock ownership to the 27,223 shares. Before that another transaction happened on Jul 22 ’25, when Company’s Chief Accounting Officer sold 238 for $4.00, making the entire transaction worth $952. This insider now owns 9,475 shares in total.
Karyopharm Therapeutics Inc (KPTI) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -3.9 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -3.92) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.57% during the next five years compared to 27.91% growth over the previous five years of trading.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Check out the current performance indicators for Karyopharm Therapeutics Inc (KPTI). In the past quarter, the stock posted a quick ratio of 0.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -14.61, a number that is poised to hit -3.40 in the next quarter and is forecasted to reach -7.77 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Analysing the last 5-days average volume posted by the [Karyopharm Therapeutics Inc, KPTI], we can find that recorded value of 0.13 million was lower than the volume posted last year of 0.13 million. As of the previous 9 days, the stock’s Stochastic %D was 77.82%.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 76.89%, which indicates a significant increase from 76.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.74 in the past 14 days, which was higher than the 0.49 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.80, while its 200-day Moving Average is $7.12. Now, the first resistance to watch is $7.53. This is followed by the second major resistance level at $7.95. The third major resistance level sits at $8.18. If the price goes on to break the first support level at $6.88, it is likely to go to the next support level at $6.65. Should the price break the second support level, the third support level stands at $6.23.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
There are currently 8,671K shares outstanding in the company with a market cap of 61.65 million. Presently, the company’s annual sales total 145,240 K according to its annual income of -76,420 K. Last quarter, the company’s sales amounted to 37,930 K and its income totaled -37,250 K.
